On a 45-station rotary tablet press equipped with B-tooling and 19 mm × 9 mm oval punches, direct compression of SuperTab 24AN has been characterized by tablet weight variability below ±2.5% at turret speeds between 30 min⁻¹ and 60 min⁻¹ when the feed frame paddle speed remains between 20 min⁻¹ and 40 min⁻¹ and the powder bed is conditioned to 35–45% RH. Formulation addition ratios in this segment typically place SuperTab 24AN at 20% w/w to 85% w/w as the filler-binder, with low-dose active pharmaceutical ingredient fractions from 1% w/w to 10% w/w and high-dose fractions from 20% w/w to 60% w/w. The downstream process begins with dry blending in a bin blender at 20 min⁻¹ for 15 min, followed by lubrication with magnesium stearate at 0.5% w/w to 1.25% w/w for 3 min; compression uses a pre-compression force of 2 kN to 4 kN and a main compression force of 8 kN to 18 kN to achieve tablet hardness from 40 N to 90 N, friability below 0.20% under USP <1216>, disintegration below 180 s under USP <701>, and dissolution acceptance conforming to USP <711>. Compliance for this segment is anchored to the USP anhydrous lactose monograph, the current Ph. Eur. anhydrous lactose monograph, ICH Q3D, and FDA 21 CFR 211.110 for in-process blend uniformity. Terminal finished product types include immediate-release antihypertensive tablet cores, low-dose hormonal tablets, analgesic tablets, and chewable antacid tablets. The principal operational boundary is moisture-dependent: at processing relative humidity above 60%, anhydrous lactose begins to convert to α-lactose monohydrate, altering particle surface characteristics and reducing tablet tensile strength unless pre-drying is performed at 80 °C to a loss on drying not exceeding 0.5% w/w by USP <731>.

What Fill Weight Control Limits Apply When Anhydrous Lactose Is Dosed on Dosator Nozzle Machines?

During high-speed encapsulation of SuperTab 24AN on a dosator-type capsule filler equipped with 8 mm dosing nozzles, the fill weight coefficient of variation remains below 1.5% when the powder is pre-sieved through a 0.8 mm mesh and the dosator nozzle compression is set to 0.5 mm to 1.0 mm. The composition typically incorporates 20% w/w to 70% w/w SuperTab 24AN, 0.25% w/w to 0.75% w/w colloidal silicon dioxide as glidant, and 0.5% w/w magnesium stearate as lubricant. Active pharmaceutical ingredient fractions from 2% w/w to 25% w/w are dry-blended for 10 min to 15 min at 20 min⁻¹ before lubrication to achieve blend uniformity monitored by near-infrared spectroscopy. The downstream encapsulation line fills size 0, 1, and 3 hard gelatin or hydroxypropyl methylcellulose capsule shells at target fill weights between 125 mg and 500 mg, with automatic weight sorters rejecting fill deviations outside ±3% from target as required by USP <905> uniformity of dosage units. In-process weight checks are performed at 15-minute intervals under FDA 21 CFR 211.110, and dissolution is assessed by USP <711>. Terminal finished product types include broad-spectrum antibiotic capsules, oral anticoagulant capsules, and fixed-dose combination capsules where the low hygroscopicity of anhydrous lactose protects moisture-sensitive active ingredients in capsule shells. The principal operational boundary is that dosator filling of lactose-based blends becomes erratic if the powder-bed relative humidity exceeds 55%; therefore, the encapsulation suite is maintained at 25–35% RH and 15–25 °C.

Roller-Compacted Anhydrous Lactose: Ribbon Density, Granule Size, and Re-compression Limits

After roller compaction of SuperTab 24AN on a 120 mm diameter knurled-roll compactor with a hydraulic gap from 2.0 mm to 3.5 mm, the optimum ribbon solid fraction lies between 0.58 and 0.68, beyond which granule re-compressibility declines because of work-hardening of the anhydrous lactose particles. Formulation addition ratios commonly place 40% w/w to 90% w/w SuperTab 24AN in the intragranular phase, with 0.5% w/w to 1.0% w/w magnesium stearate incorporated after milling as an external lubricant to prevent tablet capping. The production process uses roll force of 5 kN/cm to 15 kN/cm, roll speed between 2 min⁻¹ and 8 min⁻¹, and a 1,000 µm granulator screen followed by a 125 µm fines-removal sieve to limit the fine fraction and improve flow. Tablets compressed from the granules are tested for friability by USP <1216>, disintegration by USP <701>, and dissolution by USP <711>; in-process granule moisture is monitored to remain below 0.5% w/w by USP <731>. Compliance for this segment includes ICH Q6A for granule critical quality attributes, FDA 21 CFR 211.110 for in-process control, and ICH Q3D for elemental impurities. Terminal finished product types include high-dose metformin immediate-release tablets, antiretroviral combination tablets, and veterinary bolus tablets where the brittle fracture of anhydrous lactose improves granule compactability. Published data for this specific roller-compacted configuration are more limited than for direct compression; process qualification should therefore establish the exact ribbon density-to-tablet hardness correlation for each active ingredient before full-scale manufacturing.

When Terminal Sterilization Is Unavailable, Lyophilization with Crystallizing Bulking Excipients Yields Robust Cakes

Lyophilization of SuperTab 24AN as a bulking excipient for sterile injectable powders requires dissolution in Water for Injection at 2% w/v to 10% w/v, sterile filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane, and filling into Type I borosilicate glass vials under Grade A laminar airflow. Because anhydrous lactose undergoes mutarotation and recrystallization as α-lactose monohydrate during freezing, the freezing pattern must be controlled: thermal analysis of the formulation under 1 K/min cooling shows that an annealing step at -15 °C to -10 °C for 2 h to 4 h promotes complete crystallization and prevents cake collapse. Primary drying is executed at a shelf temperature of -35 °C to -30 °C and chamber pressure of 0.1 mbar to 0.2 mbar for 20 h to 40 h, followed by secondary drying at 25 °C to 40 °C until residual moisture measured by Karl Fischer titration is below 1.0% w/w. Compliance for this injectable segment is anchored to FDA 21 CFR 211.94 for drug product containers and closures, USP <71> sterility tests, USP <85> bacterial endotoxins test, USP <788> particulate matter in injections, and ICH Q3D elemental impurity assessments. Terminal finished product types include lyophilized cephalosporin injections, freeze-dried peptide products, and sterile powders for reconstitution administered by intravenous or intramuscular routes. The principal operational boundary is the reducing end group of lactose; combination with primary amine-containing active ingredients in unbuffered solutions above pH 6.0 should be avoided during holding periods to prevent Maillard adduct formation.

Stick-pack filling of SuperTab 24AN oral granules on a vertical form-fill-seal line with vibratory dosing heads requires the granule fraction to be retained between 125 µm and 850 µm to maintain a fill weight coefficient of variation below 2.0%. The formulation uses 50% w/w to 95% w/w SuperTab 24AN as the free-flowing diluent, 0.2% w/w to 0.5% w/w colloidal silicon dioxide as glidant, and 0.2% w/w to 0.5% w/w sodium stearyl fumarate as lubricant to avoid the alkaline degradation risk associated with magnesium stearate in acid-labile active ingredients. The downstream process includes dry blending in a bin blender at 20 min⁻¹ for 15 min, sieving through a 1.0 mm screen to remove agglomerates, and filling into stick-pack or sachet formats at target dose weights from 500 mg to 2,000 mg. Seal quality is monitored by validated dye penetration at -25 kPa for 30 min, and fill weight variation is assessed against Ph. Eur. 2.9.5 uniformity of mass for single-dose preparations and USP <905>. Terminal finished product types include oral rehydration salt granules, pediatric antacid granules, and low-dose elemental iron sachets. The principal operational limit is caking at bulk storage relative humidity above 55%; desiccant protection and moisture-barrier laminate packaging are required when the fill target exceeds 1,000 mg.

Because orodispersible tablet disintegration time must remain below 30 s under USP <701>, direct compression of SuperTab 24AN formulations is held to a narrow compression force window between 6 kN and 12 kN on a 27-station rotary press with 8 mm round punches to balance tablet hardness from 20 N to 40 N against rapid disintegration. The formulation addition ratio places SuperTab 24AN at 30% w/w to 75% w/w, with 4% w/w to 8% w/w superdisintegrant such as croscarmellose sodium or sodium starch glycolate, 1% w/w to 3% w/w sweetener, and 0.5% w/w to 1.0% w/w magnesium stearate. The downstream process includes pre-blending the active ingredient with a portion of SuperTab 24AN for 10 min in a low-shear mixer, adding remaining excipients, and mixing for another 10 min before compression. Compliance for orodispersible tablets includes USP <701>, USP <1216>, USP <905>, and Ph. Eur. 2.9.1; in-process hardness and weight checks are performed under FDA 21 CFR 211.110. Terminal finished product types include moisture-sensitive orodispersible tablets for ondansetron, loperamide hydrochloride, and desloratadine. The main operational hazard is tablet capping at high turret speed; production records show that reducing turret speed below 35 min⁻¹ and increasing pre-compression to 2 kN reduces capping on 8 mm tooling.